CANTO - Cell-free DNA in Acute Stroke
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Stroke Etiology
Study Overview
Brief Summary
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
- •18 years of age
Exclusion Criteria
- •Patients currently undergoing immunological therapies.
- •Patients with immunological diseases
- •Patients with systemic infections at the time of admission
Outcomes
Primary Outcomes
Stroke Etiology
Time Frame: at day 1
Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology
Secondary Outcomes
- Correlation cfDNA concentration and perfusion outcome(at day 1)
- Correlation cfDNA concentration and secondary embolism(at day 1)
- Correlation cfDNA concentration and thrombus fragmentation.(at day 1)
- Measures of cfDNA as a marker of systemic inflammation(at day 1)
- 90-day functional outcomes(up to 3 month)